Pfizer Seeks Expanded Use Of Abrysvo As Vaccine Shows Potential In 18+ Patients
Portfolio Pulse from Vandana Singh
Pfizer Inc (NYSE:PFE) released Phase 3 MONeT trial data for Abrysvo, showing potential as the first RSV vaccine for adults 18-59. The trial met its immunogenicity and safety endpoints, demonstrating non-inferior neutralizing responses compared to a previous study in older adults. Pfizer plans to seek regulatory approval to expand Abrysvo's use to adults 18 years and older. Shares of Pfizer are up 0.6% following the announcement.
April 09, 2024 | 4:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's Abrysvo vaccine shows potential as the first RSV vaccine for adults 18-59, with positive Phase 3 trial results. The company plans to seek regulatory approval for expanded use.
The positive outcome of the Phase 3 MONeT trial for Abrysvo in adults 18-59 demonstrates significant progress towards addressing an unmet medical need, potentially making it the first RSV vaccine for this age group. The announcement of these results and Pfizer's intention to seek regulatory approval for expanded use is likely to be viewed positively by investors, as reflected in the 0.6% increase in Pfizer's stock price. The potential expansion of Abrysvo's indication could lead to increased market penetration and revenue for Pfizer, supporting a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100